BioSpace News Archive

Bionet America, Inc. announces the launch of the long awaited BMVet PRO Series of Veterinary specific multiparameter monitors.

The U.S. Food and Drug Administration today approved three drugs for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.

Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.

In the last quarter of 2019, we achieved a major milestone: the full recruitment of 200 patients for Part A of our pivotal Phase 3 study, NefIgArd.

Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal third quarter ending December 31, 2019.

CollPlant (NASDAQ: CLGN) (the “Company”), a regenerative and aesthetic medicine company, announced it has entered into definitive agreements for up to $4.45 million.

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of Directors effective February 28th, 2020.

Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported financial results for the second quarter of fiscal year 2020 (2Q20) which ended December 31, 2019

SmileDirectClub, the industry pioneer and first direct-to-consumer oral care med tech platform, issues the following statement in response to an NBC Nightly News story on the company, which aired yesterday.